Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...

The newest BTK inhibitor on the market, Eli Lilly’s Jaypirca, has s | In a phase 3 trial, the newest Bruton’s tyrosine kinase inhibitor on the market, Eli Lilly’s Jaypirca, has shown its chops in a ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

AstraZeneca posted $14.46 billion in Q2 revenue, reaffirming its 2025 outlook as the FDA advances Imfinzi in gastric cancer.

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall ...

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...

AstraZeneca Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

New data showed a survival advantage with newer chronic lymphocytic leukemia (CLL) treatments for older patients who are typically underrepresented in clinical trials.

The non-Hodgkin’s lymphoma market size is expected to increase during the forecast period (2025–2034) owing to increasing incidence, advancements in targeted and precision therapies, the launch of ...